MDC Annual Neuromuscular ‘Seed Grant’ Competition Launch
MDC is very excited to announce that their Annual Neuromuscular ‘Seed Grant’ Competition has launched and are now accepting applications until Feb 2, 2021 for Translational Science Seed Grants and Clinical Health Management Grants.
During a time when health research funding is challenged due to the COVID-19 pandemic and as many like-minded organizations/agencies have had to cancel their research competitions, MDC are very grateful that they are able to continue the momentum achieved over the last several years and provide critical research funds to help accelerate the understanding of neuromuscular disorders, identify pathways for future therapies and optimize care to improve the quality of life for Canadians affected by neuromuscular disorders
For information on the scope and guidelines of this year’s competition, please visit:
https://muscle.ca/researchers/funding-guideline-deadlines/
Applications with cross-cutting applicability to multiple neuromuscular disorders under MDC’s umbrella as well as disorder-specific ones are welcomed. Special consideration will be given to relevant meritorious applications in the following disease-specific areas, through designated funds generously provided by donors: Myotonic Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Immune-mediated Myopathies, Charcot-Marie-Tooth Disease, Pediatric Neuromuscular Disorders.
The total budget per project is $60,000 for 2 years.
Key Dates:
Full Application Deadline: February 2 at 11:59 pm (EST)
Notice of Decision: April 2020
Funding Start Date: May 1, 2020
All applications are available online at proposalCENTRAL.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.